Scott Spearn on MedX’s skin cancer screening in Brazil and Spain
“It is an incredible project for MedX and we are fortunate enough to be in a position we are with Brazil. It is a population of about 210 million people and they are facing a major skin cancer problem. Meaning that it is not being detected until the late stages. i.e. states 3 and 4. Our device will help the people of Brazil detect it at its early onset…We have an exclusive distribution partner in Brazil. We have 45 salespeople trained in the use of our SIAscope on DermSecureTM. We are looking at significant revenues over the next two or three quarters.” States Scott Spearn, President and CEO of MedX Health Corp. (TSXV: MDX), in an interview with InvestorIntel’s Tracy Weslosky.
Scott went on to provide an update on MedX’s operations in Spain. He said that the company is working with a large group and a number of national organizations in Spain. They have done 1368 patients counsels which involved 2475 scans which identified 9 melanomas. Scott also said that mobile apps are not effective in detecting skin cancers. MedX’s SIAscope takes five images and reaches two millimeters below the skin and then uploads to the DermSecureTM software platform so that the images can be transmitted to a dermatologist for quick and early diagnosis. No other product does that.
To access the complete interview, click here
Disclaimer: MedX Health Corp. is an advertorial member of InvestorIntel Corp.
Raj Shah has been a member of the InvestorIntel.com team for the last nearly 9 years. Recruited from Merrill Lynch, he has over 13 years’ ... <Read more about Raj Shah>